Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.

@article{Dowsett2010PredictionOR,
  title={Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.},
  author={Mitch Dowsett and Jack M Cuzick and Christopher Wale and John F. Forbes and Elizabeth A. Mallon and Janine Salter and Emma M. Quinn and Anita K. Dunbier and Michael J. Baum and Aman U. Buzdar and Anthony Howell and Roberto Bugarini and Frederick L. Baehner and Steven Shak},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2010},
  volume={28 11},
  pages={
          1829-34
        }
}
  • M. DowsettJ. Cuzick S. Shak
  • Published 10 April 2010
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE To determine whether the Recurrence Score (RS) provided independent information on risk of distant recurrence (DR) in the tamoxifen and anastrozole arms of the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trial. [] Key Method PATIENTS AND METHODS RNA was extracted from 1,372 tumor blocks from postmenopausal patients with hormone receptor-positive primary breast cancer in the monotherapy arms of ATAC.

Figures and Tables from this paper

Risk of recurrence and chemotherapy benefit for patients with node-negative, estrogen receptor-positive breast cancer: recurrence score alone and integrated with pathologic and clinical factors.

  • G. TangJ. Cuzick N. Wolmark
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
RSPC refines the assessment of distant recurrence risk and reduces the number of patients classified as intermediate risk and showed better separation of risk in the study population.

Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype.

  • M. GnantI. Šestak J. Cuzick
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2015
PAM50 ROR score and IS can identify node-positive patient subgroups with limited risk of metastasis after endocrine therapy, for whom adjuvant chemotherapy can be spared.

Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG Oncology/National Surgical Adjuvant Breast and Bowel Proje

  • N. WolmarkE. Mamounas S. Paik
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2016
The value of extended tamoxifen therapy merits evaluation in patients with intermediate and high RS with higher ESR1 expression at initial diagnosis, suggesting the risk of LDR is relatively low for patients with low RS.

The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use

RS-guided chemotherapy decision-making resulted in a substantial modification of adjuvant chemotherapy usage in node-negative and node-positive ER+ EBC and was cost-saving versus current clinical practice.

Comparison of the prognostic and predictive utilities of the 21-gene Recurrence Score assay and Adjuvant! for women with node-negative, ER-positive breast cancer: results from NSABP B-14 and NSABP B-20

Prognostic estimates can be optimized by combining RS and clinicopathologic information instead of simply combiningRS and Adjuvant, and RS should be used for estimating relative chemotherapy benefit.

Predictive and Prognostic Value of the 21-Gene Recurrence Score in Hormone Receptor–positive, Node-positive Breast Cancer

  • A. Brufsky
  • Medicine
    American journal of clinical oncology
  • 2014
A systematic review of published literature from key clinical trials that have used the 21-gene breast cancer assay in patients with ER+, N+ EBC indicated that a reduction in Recurrence Score–directed chemotherapy is cost-effective and could help guide treatment decisions for patients who are most likely to receive benefit from chemotherapy.

The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis

Clinicians should be cautious when considering omission of adjuvant chemotherapy in patients with node-positive patients with low to intermediate RS, with HR+, HER2−, N1 tumors and a RS 12–25, at least until the results of the anticipated RxPONDER trial become available.

Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer

  • P. PoorvuS. Gelber A. Partridge
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2019
The RS assay is prognostic among young women with node-negative and limited node-positive breast cancer, representing a valuable tool for risk stratification.
...

References

SHOWING 1-10 OF 21 REFERENCES

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.

  • S. PaikG. Tang N. Wolmark
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2006
The RS assay not only quantifies the likelihood of breast cancer recurrence in women with node-negative, estrogen receptor-positive breast cancer, but also predicts the magnitude of chemotherapy benefit.

A population-based study of tumor gene expression and risk of breast cancer death among lymph node-negative patients

In this large, population-based study of lymph node-negative patients not treated with chemotherapy, the Recurrence Score was strongly associated with risk of breast cancer death among ER-positive, tamoxifen-treated and -untreated patients.

A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.

The recurrence score has been validated as quantifying the likelihood of distant recurrence in tamoxifen-treated patients with node-negative, estrogen-receptor-positive breast cancer and could be used as a continuous function to predict distant recurrent in individual patients.

Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the Arimidex, Tamoxifen, Alone or in Combination trial.

  • M. DowsettC. Allred A. Buzdar
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
Quantitative expression of ER and PgR and HER-2 status did not identify patients with differential relative benefit from anastrozole over tamoxifen: TTR was longer for anast rozole than for tamoxIFen in all molecular subgroups.

Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features.

  • L. GoldsteinR. Gray J. Sparano
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
The 21-gene assay was a more accurate predictor of relapse than standard clinical features for individual patients with HR-positive operable breast cancer treated with chemohormonal therapy and provides information that is complementary to features typically used in anatomic staging, such as tumor size and lymph node involvement.

Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer.

  • L. GianniM. Zambetti S. Shak
  • Biology, Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2005
Quantitative expression of ER-related genes, proliferation genes, and immune- related genes are strong predictors of pCR in women with locally advanced breast cancer receiving neoadjuvant anthracyclines and paclitaxel, suggesting that the patients who are at greatest recurrence risk are more likely to have chemotherapy benefit.

Gene expression patterns in formalin-fixed, paraffin-embedded core biopsies predict docetaxel chemosensitivity in breast cancer patients

RT-PCR technology provides a potential platform for a predictive test of docetaxel chemosensitivity using small amounts of routinely processed material.

Molecular response to aromatase inhibitor treatment in primary breast cancer

These findings identify the transcriptional signatures associated with aromatase inhibitor treatment of primary breast tumours and should enable identification of estrogen-dependent molecular changes, which are the determinants of benefit or resistance to endocrine therapy.